title: Association of ERCC1 SNPs with outcome in platinum-treated patients with advanced urothelial cancer: a Hellenic Cooperative Oncology Group study.
abstract: OBJECTIVE
  The association between two polymorphisms of ERCC1 and treatment outcomes after platinum-based chemotherapy in patients with advanced urothelial cancer (UC) was examined.
  
  
  METHODS
  Genotyping of 19007C>T and 8092C>A polymorphisms was determined by PCR amplification and RFLP in 113 advanced UC patients, treated with platinum-based chemotherapy.
  
  
  RESULTS
  Seventy eight patients (69%) were carriers of the 19007T polymorphic allele: 51 (45%) heterozygotes and 27 (24%) homozygotes. Fifty three (47%) patients were carriers of the 8092A polymorphic allele: the frequencies of C/A and A/A genotypes were 37% and 10%, respectively. The T/T genotype was independently associated with prolonged median cancer-specific survival (not-reached vs 14.8 months; p = 0.026). There was no interaction between T/T or any other genotype with the type of platinum derivative (cisplatin/carboplatin).
  
  
  CONCLUSIONS
  19007C>T, especially in its homozygotic state, but not 8092C>A polymorphism, could be a useful prognostic marker in advanced UC treated with platinum-based chemotherapy.
authors.affiliation: Department of Clinical Therapeutics, University of Athens Medical School, Oncology Unit, Alexandra Hospital, 80 Vas. Sofias Avenue, 115 28 Athens, Greece.
authors.forename: Nikitas
authors.initials: N
authors.lastname: Nikitas
authors.forename: Alexandra
authors.initials: A
authors.lastname: Karadimou
authors.forename: Eliza
authors.initials: E
authors.lastname: Tsitoura
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Soupos
authors.forename: Marinos
authors.initials: M
authors.lastname: Tsiatas
authors.forename: Vasilios
authors.initials: V
authors.lastname: Karavasilis
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Pectasides
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Pavlidis
authors.forename: Michael
authors.initials: M
authors.lastname: Chrisofos
authors.forename: Ioannis
authors.initials: I
authors.lastname: Adamakis
authors.forename: Samuel
authors.initials: S
authors.lastname: Murray
authors.forename: Georgios
authors.initials: G
authors.lastname: Fountzilas
authors.forename: Meleios-Athanasios
authors.initials: MA
authors.lastname: Dimopoulos
authors.forename: Aristotle
authors.initials: A
authors.lastname: Bamias
mesh_terms: D000368:Aged; D054316:Biomarkers, Pharmacological; D004268:DNA-Binding Proteins / Q000235:genetics*; D018572:Disease-Free Survival; D004720:Endonucleases / Q000235:genetics*; D005260:Female; D056726:Genetic Association Studies; D005838:Genotype; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010984:Platinum / Q000008:administration & dosage*; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D016896:Treatment Outcome; D014571:Urologic Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology
chemical_list: D054316:Biomarkers, Pharmacological; D004268:DNA-Binding Proteins; D010984:Platinum; C071447:ERCC1 protein, human; D004720:Endonucleases